Form 4: Nuvalent Director Matthew Shair Executes Stock Sales Under 10b5-1 Plan

Matthew Shair, a director at Nuvalent, Inc., sold shares of Class A Common Stock on July 29, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 29, 2024, Matthew Shair, a director of Nuvalent, Inc., executed multiple sales of Class A Common Stock.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on December 21, 2023.
• A total of 1,200 shares were sold at a weighted average price of $78.93, with individual prices ranging from $78.42 to $79.41.
• An additional 305 shares were sold at a weighted average price of $79.7, with prices ranging from $79.45 to $80.41.
• Further sales included 404 shares at a weighted average price of $80.98 (ranging from $80.45 to $81.44) and 91 shares at a weighted average price of $81.71 (ranging from $81.47 to $81.81).
• Following these transactions, Shair directly owns 1,427,197 shares of Class A Common Stock and indirectly owns 230,522 shares through the Matthew D. Shair 2021 Irrevocable Family Trust.
• Shair has voting and dispositive power over the shares held by the family trust.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating routine stock sales under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by insiders are a common occurrence, especially when executed under pre-arranged trading plans like Rule 10b5-1. These plans allow insiders to sell shares over a period of time without being accused of trading on inside information. The market typically views these sales in the context of the overall trading plan and the insider's remaining holdings.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
• However, given the pre-planned nature of the sales under Rule 10b5-1, the impact is likely to be minimal.

Key Dates